Filings & corporate actions
78 results filed
CSVNext results · Q2 FY27
Expected 3 Nov 2026 – 15 Nov 2026
Estimate: filed 34–46 days after quarter end, last 5 times
Dividend
₹0.10 per share · last 28 Aug 2026
2026
- 28 AugdividendDividend · ₹0.10 per share-1.4%
- 14 AugresultsResults · Q1 FY27 · consolidated and standalone-0.9%NSE
- 20 JulshareholdingShareholding · 30 Jun 2026+3.1%NSE
- 29 MayresultsResults · Q4 FY26 · consolidated and standalone+3.8%NSE
- 18 AprshareholdingShareholding · 31 Mar 2026-2.2%NSE
- 13 FebresultsResults · Q3 FY26 · consolidated and standalone-5.3%NSE
- 16 JanshareholdingShareholding · 31 Dec 2025+0.3%NSE
Reaction to results · all yearsrose on day 0 in 31 of 78 CSV
| Quarter | Filed | Day 0 | +5D | +20D | Rel vol |
|---|---|---|---|---|---|
| Q1 FY27 | 14 Aug 2026 | -0.9% | -1.0% | +0.7% | 3.5× |
| Q4 FY26 | 29 May 2026 | +3.8% | +12.8% | +21.9% | 4.4× |
| Q3 FY26 | 13 Feb 2026 | -5.3% | -8.4% | -5.1% | 3.2× |
| Q2 FY26 | 14 Nov 2025 | -1.5% | +11.1% | +9.7% | 0.7× |
| Q1 FY26 | 13 Aug 2025 | -0.1% | +1.8% | +2.9% | 1.7× |
| Q4 FY25 | 30 May 2025 | -6.4% | -5.5% | -6.9% | 4.6× |
| Q3 FY25 | 14 Feb 2025 | +0.4% | -5.9% | -15.0% | 1.6× |
| Q2 FY25 | 15 Nov 2024 | -8.3% | -8.1% | -3.8% | 0.9× |
| Q1 FY25 | 14 Aug 2024 | -0.5% | +12.5% | +17.3% | 0.8× |
| Q4 FY24 | 30 May 2024 | -1.6% | +0.6% | +13.4% | 0.7× |
| Q3 FY24 | 14 Feb 2024 | -3.0% | -5.2% | -12.2% | 0.8× |
| Q2 FY24 | 9 Nov 2023 | -1.6% | +11.6% | +21.9% | 1.1× |
| Q1 FY24 | 11 Aug 2023 | +4.0% | +0.7% | +7.1% | 1.0× |
| Q4 FY23 | 29 May 2023 | -4.7% | -6.7% | +9.4% | 3.0× |
| Q3 FY23 | 10 Feb 2023 | -3.1% | -2.3% | -7.7% | 1.4× |
| Q2 FY23 | 11 Nov 2022 | -4.2% | -7.7% | -2.1% | 2.2× |
| Q1 FY23 | 12 Aug 2022 | -1.0% | -2.9% | +13.3% | 2.1× |
| Q4 FY22 | 20 May 2022 | -6.2% | -8.7% | -17.8% | 0.8× |
| Q3 FY22 | 10 Feb 2022 | -3.5% | -9.8% | -2.5% | 0.5× |
| Q2 FY22 | 3 Nov 2021 | -2.9% | +1.8% | -0.9% | 0.7× |
| Q1 FY22 | 11 Aug 2021 | +13.4% | +2.1% | +3.1% | 16.5× |
| Q4 FY21 | 7 Jun 2021 | -2.3% | -4.0% | -3.3% | 0.3× |
| Q3 FY21 | 8 Feb 2021 | +0.1% | -1.7% | -3.2% | 2.7× |
| Q2 FY21 | 12 Nov 2020 | -3.4% | -8.3% | -5.4% | 1.9× |
| Q1 FY21 | 15 Sept 2020 | +5.4% | +1.1% | +10.5% | 2.1× |
| Q4 FY20 | 1 Aug 2020 | +4.2% | -2.1% | -15.4% | 1.9× |
| Q3 FY20 | 14 Feb 2020 | -7.7% | -5.6% | -30.7% | 1.4× |
| Q2 FY20 | 4 Dec 2019 | -1.7% | -8.0% | -3.7% | 0.9× |
| Q1 FY20 | 14 Aug 2019 | -1.0% | +9.1% | +20.5% | 2.5× |
| Q3 FY19 | 26 Feb 2019 | -4.0% | +11.8% | +7.8% | 0.7× |
| Q2 FY19 | 26 Nov 2018 | -1.1% | -5.5% | -0.4% | 1.6× |
| Q1 FY19 | 25 Aug 2018 | -1.7% | -5.0% | -5.1% | 0.4× |
| Q4 FY18 | 25 Jun 2018 | -1.7% | -0.7% | -5.9% | 0.3× |
| Q3 FY18 | 28 Feb 2018 | -0.1% | -8.2% | -4.6% | 0.4× |
| Q2 FY18 | 26 Dec 2017 | +3.8% | +7.4% | -0.4% | 1.3× |
| Q1 FY18 | 20 Sept 2017 | +1.1% | +5.9% | +17.3% | 1.7× |
| Q4 FY17 | 18 Jun 2017 | +0.6% | -1.4% | +3.0% | 0.9× |
| Q3 FY17 | 21 Feb 2017 | -1.6% | -2.7% | +12.9% | 0.3× |
| Q2 FY17 | 17 Nov 2016 | -3.7% | +5.6% | +18.6% | 0.2× |
| Q1 FY17 | 16 Nov 2016 | -2.5% | +1.8% | +17.0% | 0.2× |
| Q4 FY16 | 31 May 2016 | +0.7% | +11.4% | +7.5% | 0.7× |
| Q3 FY16 | 12 Feb 2016 | +8.8% | +6.4% | +18.6% | 1.5× |
| Q2 FY16 | 10 Nov 2015 | +0.1% | +25.7% | +31.9% | 0.2× |
| Q1 FY16 | 17 Aug 2015 | +19.8% | +17.8% | +7.3% | 2.0× |
| Q4 FY15 | 4 Jun 2015 | -0.7% | -5.5% | +11.3% | 0.2× |
| Q3 FY15 | 19 Feb 2015 | -1.7% | -2.1% | -15.3% | 1.3× |
| Q2 FY15 | 21 Nov 2014 | -3.5% | -7.6% | -15.5% | 0.8× |
| Q1 FY15 | 20 Aug 2014 | +17.2% | +40.7% | +57.5% | 7.2× |
| Q4 FY14 | 6 Jun 2014 | -0.6% | -9.7% | +63.6% | 0.9× |
| Q3 FY14 | 27 Feb 2014 | -2.0% | +7.0% | +2.0% | 0.6× |
| Q2 FY14 | 25 Nov 2013 | -1.8% | +7.3% | +4.5% | 0.0× |
| Q1 FY14 | 16 Aug 2013 | -4.4% | +15.6% | +15.6% | 0.3× |
| Q4 FY13 | 20 Jun 2013 | +1.8% | +0.9% | -8.1% | 1.4× |
| Q3 FY13 | 26 Feb 2013 | -2.2% | -4.3% | -6.5% | 0.4× |
| Q2 FY13 | 10 Nov 2012 | +9.0% | -6.3% | -2.8% | 3.4× |
| Q1 FY13 | 23 Aug 2012 | -3.9% | -15.1% | -14.5% | 0.1× |
| Q4 FY12 | 16 May 2012 | -0.7% | +7.6% | -7.6% | 0.8× |
| Q3 FY12 | 16 Feb 2012 | +0.9% | -4.3% | -12.9% | 0.8× |
| Q2 FY12 | 16 Nov 2011 | -3.3% | -8.9% | -12.2% | 0.0× |
| Q1 FY12 | 17 Aug 2011 | -2.7% | -7.1% | +16.8% | 0.2× |
| Q4 FY11 | 12 May 2011 | -4.3% | +2.1% | +13.5% | 1.0× |
| Q3 FY11 | 16 Feb 2011 | +3.3% | -7.4% | -5.0% | 0.5× |
| Q2 FY11 | 15 Nov 2010 | -2.1% | -7.0% | -8.5% | 1.0× |
| Q1 FY11 | 11 Aug 2010 | +1.4% | 0.0% | +1.4% | 3.6× |
| Q4 FY10 | 8 May 2010 | +3.8% | -0.8% | -10.8% | 1.2× |
| Q3 FY10 | 29 Jan 2010 | +0.7% | 0.0% | -7.6% | 0.1× |
| Q2 FY10 | 2 Nov 2009 | +2.7% | +2.7% | +10.8% | 0.6× |
| Q1 FY10 | 4 Aug 2009 | +5.5% | -2.7% | +17.3% | 1.7× |
| Q4 FY09 | 30 Apr 2009 | +5.6% | -4.4% | +67.8% | 0.3× |
| Q3 FY09 | 31 Jan 2009 | -3.8% | 0.0% | -19.0% | 1.7× |
| Q2 FY09 | 1 Nov 2008 | +9.0% | +24.4% | +9.0% | 0.2× |
| Q1 FY09 | 31 Jul 2008 | 0.0% | +6.9% | -3.1% | 0.7× |
| Q4 FY08 | 1 May 2008 | +0.9% | -5.7% | -13.2% | 0.5× |
| Q3 FY08 | 2 Feb 2008 | +4.9% | +0.4% | -10.3% | 0.7× |
| Q2 FY08 | 31 Oct 2007 | 0.0% | -3.9% | +15.5% | 1.2× |
| Q1 FY08 | 1 Aug 2007 | +1.0% | -0.5% | -1.0% | 1.0× |
| Q4 FY07 | 3 May 2007 | +19.3% | +8.0% | +10.4% | 3.9× |
| Q3 FY07 | 3 Feb 2007 | +19.4% | +4.1% | -19.4% | 9.6× |
| Average | +0.6% | +0.7% | +3.4% | ||
Close-to-close from the session before the filing could trade. Day 0 is the first session after it.
Growth · Q1 FY27
CSVRevenue YoY+16.6%
Profit YoY+70.7%
Interest cost YoY+32.4%
Revenue QoQ+3.6%
Profit QoQ+1.9%
| CAGR | 2Y | 3Y | 4Y | 5Y | 6Y | 7Y |
|---|---|---|---|---|---|---|
| Revenue | +9.8% | — | — | — | — | — |
| Profit | -7.8% | — | — | — | — | — |
Key data
CSVOpen419.70
Day range414.80 – 432.40
52-week range268.00 – 467.80
From 52w high-8.6%
RSI (14)51.4
ATR (14)18.20
Volume68.1K
Avg volume (20D)98.3K
Rel volume0.69×
Volatility (1Y)34.9%
Turnover₹2.9Cr
SMA 50 / 200419.76 / 346.98
Delivery percentage
Latest · 6 Oct 202646.6%
20-day avg51.9%
1-year avg52.2%
Percentile (own history)32nd
Range8.7–96.0%
Sessions1,731
Over the last 20 sessions GUFICBIO settled 51.9% of its traded quantity, which is above average for an NSE equity. That is in line with its own one-year average of 52.2%. The latest session ranks higher than 32% of the 1,731 sessions on record for it.
What delivery percentage measuresScan the whole market on delivery
IndustryPharmaceuticals
Performance returns
CSV| 1D | 1W | 1M | 3M | 6M | 1Y | |
|---|---|---|---|---|---|---|
| Price | +1.93% | +1.76% | -2.63% | +12.46% | +48.23% | +19.50% |
Valuation
CSVMarket cap₹4,290 Cr
P/E (TTM)58.4
EPS (TTM)7.32
Shares outstanding10.03Cr
Listed19 Oct 2004
Ownership
CSVPromoter72.50%
Promoter Δ QoQ0.00 pp
Public27.50%
FII0.46%
DII3.68%
Pledged0.00%
Quarterly results · consolidated
CSV| Q2 FY26 | Q3 FY26 | Q4 FY26 | Q1 FY27 | |
|---|---|---|---|---|
| Revenue (₹ Cr) | 237.1 | 231.4 | 251.8 | 260.8 |
| YoY chg | +16.1% | +11.4% | +22.8% | +16.6% |
| Net profit (₹ Cr) | 16.8 | 12.4 | 21.9 | 22.3 |
| YoY chg | -22.7% | -35.6% | +183.6% | +70.7% |
| Net margin | 7.1% | 5.4% | 8.7% | 8.6% |
| EPS | 1.68 | 1.24 | 2.18 | 2.22 |
Shareholding over time
CSVBy quarter
30 Jun 2026 · promoter 72.50% · public 27.50%2021-092026-06
- Promoter
- Public and others
- Promoter
- 72.50%
- Public
- 27.50%
- Promoter change
- 0.00 pp
- Filed
- 20 Jul 2026
- FII
- 0.46%
- DII
- 3.68%
- Promoter pledged
- 0.00%
Promoter and public shares of total equity, from the pattern filed each quarter. Institutional and pledge figures come from a separate filing stage whose backfill is still running, so they are absent for almost every instrument rather than zero.
Financials · quarterly statement
CSV₹ crore, as filed
| Q2 FY24 | Q3 FY24 | Q4 FY24A | Q1 FY25 | Q2 FY25 | Q3 FY25 | Q4 FY25A | Q1 FY26 | Q2 FY26 | Q3 FY26 | Q4 FY26A | Q1 FY27 | Trend | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue from operations | 214.9 | 201.8 | 195.0 | 202.8 | 204.2 | 207.8 | 205.0 | 223.7 | 237.1 | 231.4 | 251.8 | 260.8 | |
| Other income | 0.3 | 0.4 | 0.9 | 1.3 | 0.1 | 1.9 | 0.4 | 0.9 | 2.1 | 0.8 | (1.2) | 0.5 | |
| Total income | 215.2 | 202.2 | 195.9 | 204.1 | 204.3 | 209.7 | 205.4 | 224.6 | 239.2 | 232.2 | 250.6 | 261.3 | |
| Total expenses | 184.3 | 172.6 | 168.8 | 176.0 | 175.0 | 183.4 | 194.9 | 207.4 | 216.6 | 214.5 | 221.7 | 231.2 | |
| └ Finance costs | 4.5 | 3.2 | 3.6 | 4.6 | 5.2 | 4.9 | 8.4 | 9.2 | 9.6 | 8.4 | 9.4 | 9.3 | |
| └ Depreciation | 4.3 | 4.1 | 4.3 | 4.3 | 4.3 | 4.6 | 7.8 | 7.7 | 7.8 | 7.7 | 7.6 | 7.7 | |
| Profit before tax | 30.9 | 29.6 | 27.1 | 28.1 | 29.3 | 26.3 | 10.5 | 17.3 | 22.6 | 17.7 | 29.0 | 30.0 | |
| Tax expense | 7.7 | 7.3 | 7.1 | 7.2 | 7.5 | 7.0 | 2.8 | 4.2 | 5.8 | 5.3 | 7.1 | 7.7 | |
| Net profit | 23.2 | 22.3 | 20.0 | 20.9 | 21.8 | 19.3 | 7.7 | 13.1 | 16.8 | 12.4 | 21.9 | 22.3 | |
| EPS | 2.39 | 2.23 | 2.00 | 2.08 | 2.17 | 1.93 | 0.77 | 1.30 | 1.68 | 1.24 | 2.18 | 2.22 | |
| Net margin | 10.80% | 11.03% | 10.28% | 10.28% | 10.66% | 9.29% | 3.77% | 5.84% | 7.10% | 5.37% | 8.70% | 8.55% | |
| PBT margin | 14.40% | 14.65% | 13.91% | 13.86% | 14.33% | 12.64% | 5.13% | 7.72% | 9.54% | 7.66% | 11.50% | 11.52% | |
| Tax rate | 25.00% | 24.70% | 26.08% | 25.79% | 25.59% | 26.49% | 26.65% | 24.34% | 25.58% | 29.89% | 24.37% | 25.72% |
A audited · R restated by a later filing · negatives in parentheses. EPS and the share count are restated onto the same split-adjusted basis as the price chart, so they can be read against it; every rupee figure is exactly as filed. A quarterly filing carries a profit and loss only — there is no balance sheet behind it, and so no debt, cash flow or return-on-capital figure here. Latest filed 14 Aug 2026.
GUFICBIO at a glance
- GUFICBIO closed at ₹427.8 on 6 Oct 2026, +1.93% on the day, +19.5% over one year, 8.6% below its 52-week high of ₹467.8.
- Delivery was 46.6% of traded quantity on 6 Oct 2026, the 32nd percentile of its own 1,731 sessions with a reading (20-session average 51.9%, 1-year average 52.2%).
- Market capitalisation is ₹4,290 crore at a trailing P/E of 58.4 (trailing EPS ₹7.32).
- Q1 FY27 results (consolidated, filed 14 Aug 2026): revenue ₹261 crore (+16.6% year on year), net profit ₹22 crore (+70.7%); the price moved -0.9% on the first session after.
- Promoters held 72.50% at 30 Jun 2026, unchanged on the previous filing.
- Q2 FY27 results are expected between 3 Nov 2026 and 15 Nov 2026, going by past filing dates — an estimate, not an announcement.
About
CSVMacro sectorHealthcare
Basic industryPharmaceuticals
ISININE742B01025
SeriesEQ
Listed19 Oct 2004
History from19 Oct 2004
Sessions5,402
Prices are adjusted for splits and bonuses. Delivery figures come from NSE’s daily reports and are unavailable for older sessions. Sourced from the eod2 dataset, last updated 6 Oct 2026.
More in Pharmaceuticals & Biotechnology
CSV- DIVISLABDivi's Laboratories Limited9,550.00+3.85%
- LAURUSLABSLaurus Labs Limited2,050.00+3.99%
- SUNPHARMASun Pharmaceutical Industries Limited1,804.10+1.37%
- WOCKPHARMAWockhardt Limited2,176.40+5.47%
- DRREDDYDr. Reddy's Laboratories Limited1,208.00+0.42%
- MOREPENLABMorepen Laboratories Limited143.96+6.41%
- ZYDUSLIFEZydus Lifesciences Limited1,159.50+1.80%
- SYMBIOTECSYMBIOTEC1,149.50-1.73%
- TORNTPHARMTorrent Pharmaceuticals Limited4,772.000.00%
- GLANDGland Pharma Limited3,006.10+3.25%
- LUPINLupin Limited2,029.30+0.91%
- AUROPHARMAAurobindo Pharma Limited1,692.80+1.07%
All Pharmaceuticals & Biotechnology stocks on the NSEAll Healthcare stocks on the NSE